Search

Displaying results 1211 - 1220 of 5384 in total
  1. Drug

    Vilanterol

    go.drugbank.com/drugs/DB09082
    ApprovedInvestigational

    [A7738,A259961] Vilanterol is approved for use in several combination products such as with [fluticasone furoate] under the tradename BREO ELLIPTA, with [umeclidinium bromide] as ANORO ELLIPTA, and … [L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020.

  2. Drug

    Proguanil

    go.drugbank.com/drugs/DB01131
    Approved

    It does this by inhibiting the enzyme, dihydrofolate reductase, which is involved in the reproduction of the parasite. … Proguanil is a prophylactic antimalarial drug, which works by stopping the malaria parasite, _Plasmodium falciparum_ and _Plasmodium vivax_, from reproducing once it is in the red blood cells.

  3. Drug

    Lasmiditan

    go.drugbank.com/drugs/DB11732
    ApprovedInvestigational

    suitable for use in patients with pre-existing cardiovascular disorders. … [sumatriptan]) have seen preferential use in the acute treatment of migraines due to their relatively favourable efficacy and safety.

  4. Drug

    Finafloxacin

    go.drugbank.com/drugs/DB09047
    ApprovedWithdrawn

    Finafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014. … Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.

  5. Drug

    Rotavirus vaccine

    go.drugbank.com/drugs/DB10276
    ApprovedInvestigational

    Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rot...

    Categories: Antiinfectives for Systemic Use
  6. Drug

    Diatrizoate

    go.drugbank.com/drugs/DB00271
    ApprovedVet approved

    A commonly used x-ray contrast medium. As diatrizoate meglumine and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.

    Mixtures: Hypaque-M Liq 76% USP, Hypaque-M Liq 76% USP
  7. Drug

    Voxelotor

    go.drugbank.com/drugs/DB14975
    Approved

    The EMA approved the use of voxelotor for the treatment of hemolytic anemia associated with sickle cell disease in February 2022.[L41419,L41424] … [L10403] It was developed by Global Blood Therapeutics, Inc.

  8. Drug

    Tetrahydrofolic acid

    go.drugbank.com/drugs/DB00116
    InvestigationalNutraceutical

    Tetrahydrofolic acid is a folic acid derivative that is produced from dihydrofolic acid after conversion by dihydrofolate reductase. … It is converted into 5,10-methylenetetrahydrofolate by serine hydroxymethyltransferase. It is a soluble coenzyme in many reactions, especially in the metabolism of amino acids and nucleic acids.

  9. Drug

    Sparsentan

    go.drugbank.com/drugs/DB12548
    ApprovedInvestigational

    [A257330] In February 2023, the use of sparsentan to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression was approved by the FDA under … [L45315] The use of sparsentan may cause hepatotoxicity and embryo-fetal toxicity.

  10. Drug

    Miltefosine

    go.drugbank.com/drugs/DB09031
    ApprovedInvestigational

    Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent. It is currently the only recognized oral agent used to treat visceral, cutaneous, and ...